Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
PMID: 31521809
2019
International journal of antimicrobial agents
Abstract: In patients with time of virological suppression <88 months, the rate of VF was higher in the presence of the M184V mutation.
Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County.
Discussion: Interestingly, we would expect the subsequent appearance of TDF/FTC-associated mutations, but we only observed one case of M184V in 2006 and zero cases of K65R, which are major NRTI mutations selected for by FTC/3TC and TDF, respectively.
Discussion: This may be due to the lower selectivity of FTC for M184V and the inhibitive action of M184V and K65R on viral fitness.
Molecular Genetics and the Incidence of Transmitted Drug Resistance Among Pre-Treatment HIV-1 Infected Patients in the Eastern Cape, South Africa.
Abstract: K103N/S, V106M and M184V were the most common mutations identified among the viral sequences.
HIV-1 subtype diversity, drug resistance, and genetic transmission networks in men who have sex with men with virologic failure in antiretroviral therapy in Sichuan, China, 2011 to 2017.
Abstract: The most common drug resistance-associated mutations in protease inhibitors (PIs), NRTIs and NNRTIs were K20I/R, M184V/I and K103N/KN, respectively.
Result: M184V/I (236/372, 63.44%), K65KR/R (78/372, 20.97%), D67DN/N (77/372, 20.70%), and K70E/R/KR (72/372, 19.35%) were most common NRTI-related mutations.
Discussion: M184V/I may alter the optimal binding of NRTIs and decrease 3TC removal and enzymatic processivity, and results i
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 31660328
2019
Open forum infectious diseases
Discussion: A recent subgroup analysis of this study showed that the response rate of DTG also was high when 3TC or FTC was used in the presence of a M184V/I mutation.
Discussion: Although most were small trials (less than 500 patients) originating from single cohorts, they all described low VF rates, irrespective of the presence of the M184V/I mutation.
Discussion: Although the unweighted univariate analysis showed that M184V/I had a significant effect on the increase of the risk of the composite outcome, including both VBs and VF, this effect was no longer statistically significant in the IPW analysis.
Discussion: Furthermore, among 126 patients treated with a 3TC/DTG-containing regimen and followed for a median of 1.3 years, VF was detected in none of 21 patients with the M184V/I mutation and in 2 of 105 patie
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Abstract: The phylogenetic analyses of the amplified region of pol gene indicated that all of the 15 HIV-1-infected pediatric patients were infected by CRF35_AD, and a total of 13.3% (2/15) of these children were infected with HIV-1 variants with SDRMs (one child harbored two related SDRMs [D67N, V179F], and another child had three related SDRMs [M184V, T215F, and K103N]), according to the last algorithm of the WHO.
[Postmortem Molecular Epidemiology of HIV-1 Strains Isolated in Turkey].
HIV mutation literature information.
PMID: 
2019
International journal of antimicrobial agents
Browser Board
Co-occurred Entities
Filtrator
ViMRT